162 related articles for article (PubMed ID: 22243975)
1. Correlation between p38 mitogen-activated protein kinase and human telomerase reverse transcriptase in sarcomas.
Matsuo T; Shimose S; Kubo T; Fujimori J; Yasunaga Y; Sugita T; Ochi M
J Exp Clin Cancer Res; 2012 Jan; 31(1):5. PubMed ID: 22243975
[TBL] [Abstract][Full Text] [Related]
2. Telomere-maintenance mechanisms in soft-tissue malignant fibrous histiocytomas.
Matsuo T; Shay JW; Wright WE; Hiyama E; Shimose S; Kubo T; Sugita T; Yasunaga Y; Ochi M
J Bone Joint Surg Am; 2009 Apr; 91(4):928-37. PubMed ID: 19339578
[TBL] [Abstract][Full Text] [Related]
3. Molecular mechanisms for the p38-induced cellular senescence in normal human fibroblast.
Harada G; Neng Q; Fujiki T; Katakura Y
J Biochem; 2014 Nov; 156(5):283-90. PubMed ID: 24920674
[TBL] [Abstract][Full Text] [Related]
4. Telomerase activity and human telomerase reverse transcriptase mRNA expression are correlated with clinical aggressiveness in soft tissue tumors.
Tomoda R; Seto M; Tsumuki H; Iida K; Yamazaki T; Sonoda J; Matsumine A; Uchida A
Cancer; 2002 Sep; 95(5):1127-33. PubMed ID: 12209700
[TBL] [Abstract][Full Text] [Related]
5. Alternative lengthening of telomeres as a prognostic factor in malignant fibrous histiocytomas of bone.
Matsuo T; Shimose S; Kubo T; Fujimori J; Yasunaga Y; Ochi M
Anticancer Res; 2010 Dec; 30(12):4959-62. PubMed ID: 21187476
[TBL] [Abstract][Full Text] [Related]
6. The expression of c-Met pathway components in unclassified pleomorphic sarcoma/malignant fibrous histiocytoma (UPS/MFH): a tissue microarray study.
Lahat G; Zhang P; Zhu QS; Torres K; Ghadimi M; Smith KD; Wang WL; Lazar AJ; Lev D
Histopathology; 2011 Sep; 59(3):556-61. PubMed ID: 22034893
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathologic significance of telomerase activity and hTERT mRNA expression in non-small cell lung cancer.
Hara H; Yamashita K; Shinada J; Yoshimura H; Kameya T
Lung Cancer; 2001 Nov; 34(2):219-26. PubMed ID: 11679180
[TBL] [Abstract][Full Text] [Related]
8. IFN-α inhibits telomerase in human CD8⁺ T cells by both hTERT downregulation and induction of p38 MAPK signaling.
Lanna A; Coutavas E; Levati L; Seidel J; Rustin MH; Henson SM; Akbar AN; Franzese O
J Immunol; 2013 Oct; 191(7):3744-52. PubMed ID: 23997212
[TBL] [Abstract][Full Text] [Related]
9. Prognostic potential of the telomerase subunit human telomerase reverse transcriptase in tumor tissue and nontumorous mucosa from patients with colorectal carcinoma.
Gertler R; Rosenberg R; Stricker D; Werner M; Lassmann S; Ulm K; Nekarda H; Siewert JR
Cancer; 2002 Nov; 95(10):2103-11. PubMed ID: 12412163
[TBL] [Abstract][Full Text] [Related]
10. Telomerase activity and hTERT mRNA expression can be heterogeneous and does not correlate with telomere length in soft tissue sarcomas.
Yan P; Benhattar J; Coindre JM; Guillou L
Int J Cancer; 2002 Apr; 98(6):851-6. PubMed ID: 11948462
[TBL] [Abstract][Full Text] [Related]
11. Real-time PCR quantification of human telomerase reverse transcriptase (hTERT) in colorectal cancer.
Saleh S; Lam AK; Ho YH
Pathology; 2008 Jan; 40(1):25-30. PubMed ID: 18038311
[TBL] [Abstract][Full Text] [Related]
12. Mitogen-activated protein kinase cascade-mediated histone H3 phosphorylation is critical for telomerase reverse transcriptase expression/telomerase activation induced by proliferation.
Ge Z; Liu C; Björkholm M; Gruber A; Xu D
Mol Cell Biol; 2006 Jan; 26(1):230-7. PubMed ID: 16354694
[TBL] [Abstract][Full Text] [Related]
13. Quantitative assessment of telomerase activity and human telomerase reverse transcriptase messenger RNA levels in pancreatic juice samples for the diagnosis of pancreatic cancer.
Ohuchida K; Mizumoto K; Ogura Y; Ishikawa N; Nagai E; Yamaguchi K; Tanaka M
Clin Cancer Res; 2005 Mar; 11(6):2285-92. PubMed ID: 15788678
[TBL] [Abstract][Full Text] [Related]
14. Levels of telomerase catalytic subunit mRNA as a predictor of potential malignancy.
Hisatomi H; Nagao K; Kanamaru T; Endo H; Tomimatsu M; Hikiji K
Int J Oncol; 1999 Apr; 14(4):727-32. PubMed ID: 10087321
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemistry for human telomerase reverse transcriptase catalytic subunit (hTERT): a study of 143 benign and malignant soft tissue and bone tumours.
Patel RM; Folpe AL
Pathology; 2009; 41(6):527-32. PubMed ID: 19900100
[TBL] [Abstract][Full Text] [Related]
16. Real-time quantitative analysis for human telomerase reverse transcriptase mRNA and human telomerase RNA component mRNA expressions as markers for clinicopathologic parameters in urinary bladder cancer.
Takihana Y; Tsuchida T; Fukasawa M; Araki I; Tanabe N; Takeda M
Int J Urol; 2006 Apr; 13(4):401-8. PubMed ID: 16734859
[TBL] [Abstract][Full Text] [Related]
17. Human telomerase reverse transcriptase (hTERT) gene expression in FNA samples from thyroid neoplasms.
Liou MJ; Chan EC; Lin JD; Liu FH; Chao TC
Cancer Lett; 2003 Mar; 191(2):223-7. PubMed ID: 12618337
[TBL] [Abstract][Full Text] [Related]
18. Telomerase activity and expression of the telomerase catalytic subunit, hTERT, in meningioma progression.
Simon M; Park TW; Leuenroth S; Hans VH; Löning T; Schramm J
J Neurosurg; 2000 May; 92(5):832-40. PubMed ID: 10794298
[TBL] [Abstract][Full Text] [Related]
19. Detection of telomerase status by semiquantitative and in situ assays, and by real-time reverse transcription-polymerase chain reaction (telomerase reverse transcriptase) assay in bladder carcinomas.
Longchampt E; Lebret T; Molinie V; Bieche I; Botto H; Lidereau R
BJU Int; 2003 Apr; 91(6):567-72. PubMed ID: 12656916
[TBL] [Abstract][Full Text] [Related]
20. Circulating hTERT mRNA as a tumor marker in cholangiocarcinoma patients.
Leelawat K; Leelawat S; Ratanachu-Ek T; Trubwongchareon S; Wannaprasert J; Tripongkaruna S; Chantawibul S; Tepaksorn P
World J Gastroenterol; 2006 Jul; 12(26):4195-8. PubMed ID: 16830373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
